165 results about "Lipid bilayer" patented technology

The invention relates to the field of biological medicine, in particular to a hair follicle targeted delivery system and hair growth and hair loss prevention cosmetics, the hair follicle targeted delivery system comprises: a lipid nanoparticle core which is internally loaded with a bioactive component with hair growth and hair loss prevention effects; the hair follicle targeting molecule can specifically recognize and bind to a receptor on the surface of a hair follicle cell; a targeting anchoring conjugate composed of a linker covalently linked to the hair follicle targeting molecule and an anchoring lipid; wherein the targeting anchoring conjugate is embedded into the lipid bilayer of the lipid nanoparticle core through the anchoring lipid, so that the hair follicle targeting molecule is displayed on the surface of the lipid nanoparticle core. According to the application, through an innovative targeted anchoring conjugate structure, the targeting property and enrichment efficiency of hair growth and hair loss prevention active ingredients on hair follicle tissues can be remarkably improved, and the effect that a medicine accurately acts on a focus part is ensured, so that the number of hair follicles at an alopecia areata modeling part can be remarkably increased.

The invention discloses a compound liposome, a freeze-dried powder injection as well as a preparation method and application of the freeze-dried powder injection. The compound lipidosome comprises a lipidosome membrane and an inner water phase encapsulated in the lipidosome membrane, the paclitaxel palmitate is encapsulated in a lipid bilayer of the liposome membrane; the gemcitabine or the salt thereof is encapsulated in the inner water phase; the compound liposome comprises the following raw materials: paclitaxel palmitate, lecithin, a polyethylene glycol derivative, gemcitabine or a salt thereof, an organic solvent and a buffer solution A; the molar ratio of the lecithin to the polyethylene glycol derivative is 1: (0.01-0.15). The compound liposome disclosed by the invention is relatively high in encapsulation efficiency (especially the encapsulation efficiency of PTX-PA is relatively good) and relatively high in safety, the preparation method is simple and easy to operate, the industrialization degree is high, and the prepared compound liposome has a relatively good long-circulation effect, a relatively good anti-tumor effect and good in-vivo tolerance.

The present disclosure provides methods for preparing a liposome composition. One of the methods includes the steps of: providing precursor liposomes encapsulating platinum-based precursors; and incubating the precursor liposomes with a salt solution to convert the platinum-based precursors to platinum-based drugs to form the liposome composition. The precursor liposomes are prepared by step of: hydrating the platinum-based drugs to form the platinum-based precursors; and adding the platinum-based precursors to a lipid bilayer vehicle to form the precursor liposomes. The liposome composition prepared by the methods shows improved encapsulation efficiency and enhanced drug loading capacity.

The invention relates to the technical field of biology, in particular to silymarin inclusion compound lipidosome and a preparation method and application thereof. The silymarin inclusion compound liposome is prepared from the following components in parts by weight: 10 to 48 parts of silymarin, 10 to 53 parts of phospholipid, 5 to 10 parts of Arabic gum and 25 to 70 parts of cyclodextrin. According to the invention, cyclodextrin and phospholipid are combined to form a double-drug-loading structure; on the basis, Arabic gum is used as a film-forming agent to form a protective film on the surface of the liposome, so that the stability of the system is further improved; the silymarin inclusion compound is encapsulated in a water phase in the liposome, and meanwhile, part of free silymarin is encapsulated in a lipid bilayer. According to the structure, the solubility and the encapsulation efficiency of the silymarin are remarkably improved, the liposome stability is enhanced, the drug release is effectively controlled, and the silymarin inclusion compound lipid is simple in preparation process and suitable for industrial production.

The invention relates to the technical field of medicines, in particular to application of lycium barbarum-derived extracellular vesicles in preparation of a medicine for treating acute kidney injury. The used extracellular vesicles derived from Chinese wolfberry fruits have a lipid bilayer membrane structure, are good in stability, free of remarkable toxicity, good in blood compatibility and high in-vivo safety after long-term intravenous injection, are used for preparing the medicine for treating the acute kidney injury, and can reduce apoptosis, inhibit rising of blood urea nitrogen and creatinine levels and relieve injury of kidney tissues; the invention further provides application of the extracellular vesicles derived from the Chinese wolfberry fruits in preparation of the medicine for treating the lung injury disease, the weight loss is relieved, lung tissue is protected, meanwhile, the pulmonary alveolar-capillary barrier can be repaired, and in addition, the medicine can be used for treating the lung injury disease. The invention also provides application of the extracellular vesicles derived from Chinese wolfberry fruits in preparation of nuclear transcription factor kappa B inhibitors and / or inhibition of apoptosis and / or repair of pulmonary alveolar capillary barriers.

Embodiments of the present invention include methods of targeting acidosis (low pH) within the tumor microenvironment (TME) through the use of cathodic electrochemical reactions (CER). Low pH is oncogenic by supporting immunosuppression. Electrochemical reactions create local pH effects when a current passes through an electrolytic substrate such as biological tissue. Electrolysis has been used with electroporation (destabilization of the lipid bilayer via an applied electric potential) to increase cell death areas. However, the regulated increase of pH through only the cathode electrode has been ignored as a possible method to alleviate TME acidosis, which could provide substantial immunotherapeutic benefits. Here, ex vivo modeling shows that CERs can intentionally elevate pH to an anti-tumor level and that increased alkalinity promotes activation of naïve macrophages. Embodiments of the invention include pairing CER treatment protocols with existing electric field-based cancer therapies or use as a stand-alone therapy.

The invention discloses a recombinant collagen composite nano-liposome as well as a preparation method and application thereof. The composite nano-liposome provided by the invention comprises a liposome which is provided with a closed lipid bilayer molecular layer and a content encapsulated in the closed lipid bilayer molecular layer; and a polyquaternium-51 layer that encapsulates the liposome. A supramolecular assembly, phospholipid wrapping and polyquaternium-51 protective layer is formed on the surface of the protein through a hierarchical wrapping technology, and multiple technologies are superposed, so that the stability and the transdermal absorption effect of the protein and the lipidosome are remarkably improved.

The invention relates to the technical field of biological medicines, and discloses an alpha-ketoglutaric acid composite liposome as well as a preparation method and application thereof. Alpha-ketoglutaric acid is preliminarily entrapped by lecithin and cholesterol to prepare a basic liposome, and then enzymolysis silkworm pupa protein is introduced to the surface of the liposome, so that the enzymolysis silkworm pupa protein and a lipid bilayer are subjected to hydrophobic and hydrogen-bond interaction to form a protein-lipid composite layer, and the stability of a membrane structure is enhanced; and the positively charged arginine modified starch is further deposited on the surface of the liposome to form a polysaccharide-protein-lipid composite layer, so that the electrostatic locking of the negatively charged alpha-ketoglutaric acid is realized, and the encapsulation efficiency and the controlled release performance are further improved. The alpha-ketoglutaric acid composite liposome provided by the invention has the advantages of being high in stability, safe to eat, high in encapsulation efficiency, good in gastric acid resistance stability and the like, has a good slow release characteristic, and can be applied to the fields of sports nutritional supplements, antioxidant products or anti-aging products and the like.

The present application relates to a kind of robecoxib liposome and its preparation method and application, the preparation raw material of the robecoxib liposome includes phospholipid, cholesterol and robecoxib, and the robecoxib is encapsulated in lipid bilayer, and the robecoxib liposome of the present application improves the solubility of robecoxib, and has higher encapsulation efficiency and drug loading.

The invention provides a microfluidic device (100) for the formation of lipid bilayers, wherein the microfluidic device (100) comprises a first fluid inlet (111), a first fluid outlet (112), and a first microfluidic channel (110) configured to fluidically connect the first fluid inlet (111) and the first fluid outlet (112), wherein: (A) the first microfluidic channel (110) comprises a membrane formation section (200) having a membrane formation section axis (Emfs) of elongation, wherein the channel wall (115) at the membrane formation section (200) comprises a membrane formation wall section (215); (B) the membrane formation section (200) comprises a plurality of micropillars (210); (C) the plurality of micropillars (210) are configured in an n*m array parallel to the membrane formation section axis (Emfs) of elongation; wherein n is selected from the range of ≥1 and m is selected from the range of ≥2; wherein the n*m array is configured to define (i) n+1 elongated subchannels (110a,110b,110c...) within the first microfluidic channel (110) and (ii) per row of the n rows m-1 fluidic connection sections (105); wherein each of the plurality of micropillars (210) tapers in directions parallel to the membrane formation section axis (Emfs) of elongation towards respective adjacent micropillars (210); (D) the membrane formation wall section (215) is configured in a wave-like shape parallel to the membrane formation section axis (Emfs) of elongation.

The application provides a paclitaxel liposome injection and a preparation method thereof, and belongs to the technical field of pharmaceutical preparations. The injection is prepared from the following injection-grade raw and auxiliary materials: paclitaxel, phospholipid, cholesterol, gamma-aminobutyric acid, potassium lactate, a buffer, a freeze-drying protective agent and water for injection. The gamma-aminobutyric acid and the potassium lactate are simultaneously added as the liposome membrane stabilizer, the two synergistically act, the compactness and the stability of the lipid bilayer are significantly enhanced, the paclitaxel encapsulation rate is improved, the drug leakage rate is reduced, and the long-term storage stability of the preparation is improved.

The disclosure relates to nanopore preparations with reduced concentrations of detergents including detergent-free preparations. The disclosure provides lipid nanoparticles (LNPs) comprising a lipid, saposin, and a nanopore, methods for producing such LNPs, as well as systems and methods for nanopore-based sequencing using such LNPs. The new nanopore preparation avoids the pitfalls of using detergent-based compositions, such as disrupting the interactions between a target molecule and a nanopore during sequencing, disruption of the lipid bilayer, and batch-to-batch variability in nanopore preparations.

This invention relates to the field of biomedicine, and more particularly to a hair follicle-targeted delivery system and a hair growth and anti-hair loss cosmetic. The hair follicle-targeted delivery system comprises: a lipid nanoparticle core loaded with bioactive ingredients having hair growth and anti-hair loss effects; a hair follicle-targeting molecule capable of specifically recognizing and binding to receptors on the surface of hair follicle cells; and a targeting and anchoring conjugate consisting of a linker covalently linked to the hair follicle-targeting molecule and an anchoring lipid. The targeting and anchoring conjugate is embedded in the lipid bilayer of the lipid nanoparticle core via the anchoring lipid, thereby exposing the hair follicle-targeting molecule on the surface of the lipid nanoparticle core. This application, through its innovative targeting and anchoring conjugate structure, can significantly improve the targeting and enrichment efficiency of the hair growth and anti-hair loss active ingredients on hair follicle tissue, ensuring precise drug action on the lesion site, thereby significantly increasing the number of hair follicles in the alopecia areata modeling area.

The invention discloses a transrespiratory tract noninvasive drug delivery carrier and a preparation method and application thereof.The transrespiratory tract noninvasive drug delivery carrier comprises a lipid bimolecular layer and bioactive ingredients wrapped in the lipid bimolecular layer, and the lipid bimolecular layer comprises a liposome membrane and an enzyme responsive modification part embedded into the liposome membrane; the enzyme responsive modification part is a substrate polypeptide capable of being degraded by RTC-enz and polyethylene glycol connected with the substrate polypeptide. According to the invention, an enzyme-responsive modification part is introduced to the surface of a liposome membrane, so that efficient targeted disintegration of the liposome membrane is realized in pulmonary alveoli in an RTC-enz environment. Bioactive components carried by the liposome are uniformly distributed on the surface of a'gas-blood barrier 'in the pulmonary alveolus after the liposome is disintegrated, so that effective retention and uniform dispersion can be realized, and the condition that the liposome which cannot be disintegrated blocks a'gas-liquid' barrier on the surface of the pulmonary alveolus at the end of the respiratory tract is avoided; and potential toxicity caused by transfection of bioactive components carried by liposome which cannot be disintegrated into alveolar epithelial cells is also avoided.

The present invention relates to a coating material for drug-coated balloons, drug-coated balloons, and a coating solution for drug-coated balloons, as well as their preparation and application. The coating solution comprises an aqueous solvent and a plurality of core-shell structures dispersed in the aqueous solvent, each of which comprises a lipid bilayer coated with a drug. The core of the core-shell structure contains a plurality of drug-loaded particles, and the shell of the core-shell structure is a lipid bilayer with an outer hydrophilic group and an inner hydrophobic group. The drug-loaded particles comprise a plurality of drug-loaded nanocrystalline particles. The combination of nanocrystals and liposomes combines the advantages of these two types of drug carriers. The resulting lipid bilayer improves the solubility of poorly soluble drugs in drug-coated balloons, resulting in a high drug loading capacity, high drug carrier stability, and stable drug crystal form, allowing for controllable drug release rates.

The present invention relates to compositions comprising nucleic acid-lipid particles, wherein the nucleic acid-lipid particles are characterized by encapsulation of the nucleic acid in a lipid bilayer. The present invention further relates to said compositions for use in preventing and / or treating disease, particularly for use in preventing and / or treating cancer. The present invention further relates to methods for producing compositions comprising said nucleic acid-lipid particles.

Disclosed herein are novel antimicrobial peptides with useful, improved, or superior properties such as antimicrobial activity, desirable levels of hemolytic activity, and therapeutic index against a broad range of microorganisms including gram-negative and gram-positive bacteria and other organisms having a cellular or structural component of a lipid bilayer membrane. Also provided are methods of making and using such peptides to control microbial growth and in pharmaceutical compositions for the treatment of infections caused by such microorganisms.

A computational system and method for digital modeling of cardiac cell membrane electrophysiology is disclosed. The system generates a digital model representing the cell membrane as a dielectric lipid bilayer comprising a capacitor element and a resistor element, where the resistor element is emulated by a plurality of ion channels. The system calculates cell membrane potential based on intracellular and extracellular concentrations of key ions, such as Na+, K+, Ca2+, and Cl-, using the Goldman-Hodgkin-Katz equation. Generation of cellular membrane action potentials is simulated by modeling the opening and closing of voltage-gated ion channels in response to triggering events. The model provides dynamic visualizations of the distinct phases of the action potential, including depolarization and repolarization, offering a high-fidelity tool for research and for enhancing the realism of training simulations in electrophysiology procedures.

A nanocarrier including a silica body having a surface and defining a plurality of pores that are suitable to receive molecules therein is described. The nanocarrier also includes a lipid bilayer coating the surface, and a cargo-trapping agent within the phospholipid bilayer. The phospholipid bilayer stably seals the plurality of pores. The cargo-trapping reagent can be selected to interact with a desired cargo, such as a drug.

This invention belongs to the field of cosmetic technology and discloses an anti-wrinkle essence containing Panax notoginseng oil and its preparation method. The essence comprises Panax notoginseng oil, phospholipids, a membrane flexibility regulating component, tocopheryl acetate, a polyol moisturizer, xanthan gum, carbomer, a pH adjuster, a preservative system, and water. The Panax notoginseng oil, phospholipids, the membrane flexibility regulating component, and tocopheryl acetate together constitute a flexible nanoliposome dispersion system. Panax notoginseng oil, as a functional oil phase, participates in the lipid bilayer construction and is dispersed in the aqueous essence system in a structured encapsulation form. Tocopheryl acetate exists in the flexible nanoliposomes as a membrane stabilizing component and an oil phase antioxidant protective component. The preparation method includes preparing the aqueous phase of the essence matrix, preparing a lipid phase premix containing Panax notoginseng oil, dropwise adding it to form an initial dispersion and homogenizing under high pressure, vacuum degassing, and adjusting the pH to obtain the finished product. This essence exhibits good dispersion stability, strong antioxidant capacity, and good anti-wrinkle effects.

The present application provides a method for preparing a liposome composition. In the method, a containing step is provided, including: providing precursor liposomes wrapping a platinum drug precursor; and culturing the precursor liposomes in a salt solution to convert the platinum drug precursor into a platinum drug to obtain the liposome composition. The precursor liposomes are obtained by the following steps: hydrating the platinum drug to obtain the platinum drug precursor; and adding the platinum drug precursor to a lipid bilayer carrier to obtain the precursor liposomes. The liposome composition prepared by the method has better coating rate and stronger drug loading capacity.

To provide a microfluidic device capable of operating fluid simply to form a lipid double membrane by distinguishing two flow paths into hydrophilic one and hydrophobic one, and a method for forming a lipid double membrane.SOLUTION: A microfluidic device 1 comprises: a first flow path 21 defined by a hydrophobic surface; a second flow path 22 defined by a hydrophilic surface, which extends parallel to the first flow path 21; and a connection path 23 that connects the first flow path 21 and the second flow path 22, where the second flow path 22 is filled with a first aqueous solution 31, the first flow path 21 is filled with a second aqueous solution 33, and the connection path 35 is formed with a lipid double membrane.SELECTED DRAWING: Figure 3

Provided is a viral vector having a lipid bilayer envelope, the lipid bilayer envelope comprising an antibody binding domain displayed outside the envelope, the antibody binding domain being cell type specific; a viral envelope protein exhibited outside the envelope, the viral envelope protein being capable of promoting infection of the same cell type; and a nucleic acid molecule comprising a promoter capable of being expressed in the same cell type. Methods of making the viral vectors and methods of modifying cells and treating diseases / conditions using the viral vectors are also provided.

The invention relates to the technical field of skin care, and discloses a sustained-release composition containing azelaic acid composite lipidosome and application of the sustained-release composition in acne treatment and skin repair. Comprising a composite liposome, an encapsulated active component and a dispersion medium, the composite liposome is composed of a lipid bilayer, the lipid bilayer comprises phospholipid, cholesterol and pegylated phospholipid, and the phospholipid is a mixture of hydrogenated soybean phospholipid and dipalmitoyl phosphatidylcholine; the encapsulated active component comprises a fat-soluble component and a water-soluble component; the water-soluble components comprise a hamamelis virginiana leaf water extract and a herba portulacae extract; the dispersion medium is a phosphate buffer solution; by optimizing lipid composition, introducing surface modification and constructing a multi-layer release system, the invention aims to synergistically exert multiple effects of antibiosis, anti-inflammation, cutin regulation, red fading, repair and the like, and provides an efficient, mild and integrated solution for acne and sequelae skin problems thereof.

Disclosed are: a fluorescent compound represented by general formula (I), (I)′, or (I)″, as a fluorescent compound which has high retention in a lipid bilayer, has excellent ease of handling, and can achieve uniform dyeing in a dyeing target; and a lipid bilayer dyeing method and an endocytosis detection method using said compound.Ch is a hydrophobic-field-sensitive fluorescent chromophore in which the fluorescence intensity increases in hydrophobic environments; A-H is an anionic functional group capable of generating anions by deprotonation; Xn+ is a positive ion having biological compatibility; n is 1, 2, or 3; L is a linker that binds to a hydrophobic-field-sensitive fluorescent chromophore and links the fluorescent chromophore and the anionic functional group; and LH+ indicates a state wherein the linker, which contains a cationic functional group capable of generating cations by protonation, has generated a cation by protonation.

Drug-loaded microbead compositions include microbeads of a water-swellable polymer material and a complex of a carrier and a therapeutic agent chemically bonded to the carrier. The complex is embedded in the polymer material. Methods for preparing the drug-loaded microbead compositions and embolization compositions include loading a therapeutic agent into a water-swellable polymer material to form microbeads, then removing water from the microbeads. Additional drug-loaded microbead compositions include microbeads of a biodegradable material, vesicular agents, a first therapeutic agent associated with the vesicular agents, and a second therapeutic agent different from the first therapeutic agent. The vesicular agents include a lipid bilayer surrounding a vesicular core. The second therapeutic agent is contained within the microbeads or associated with the microbeads through ionic or non-covalent interaction and may or may not be associated with the vesicular agents. Drug-loaded biodegradable microbead compositions include microbeads of biodegradable material and a therapeutic agent.

The application discloses multimeric assemblies including multiple oligomeric substructures, where each oligomeric substructure includes multiple proteins that self-interact around at least one axis of rotational symmetry, where each protein includes one or more polypeptide-polypeptide interface (“O interface”); and one or more polypeptide domain that is capable of effecting membrane scission and release of an enveloped multimeric assembly from a cell by recruiting the ESCRT machinery to the site of budding by binding to one or more proteins in the eukaryotic ESCRT complex (“L domain”); and where the multimeric assembly includes one or more subunits comprising one or more polypeptide domain that is capable of interacting with a lipid bilayer (“M domain”), as well as membrane-enveloped versions of the multimeric assemblies.

The invention discloses a quercetin nano-vesicle complex as well as a preparation method and application thereof. The preparation method of the nano-vesicles comprises the following steps: separating and purifying extracellular vesicle-like nano-particles from cow milk by combining differential centrifugation with an EDTA precipitation method; quercetin is efficiently loaded in a vesicle nanostructure by adopting an ultrasonic-assisted co-incubation technology, and a drug loading system is characterized through particle size analysis, Zeta potential determination and a transmission electron microscope. The natural lipid bilayer structure of the milk-derived extracellular vesicles is creatively utilized, the constructed quercetin nano-vesicle complex shows excellent stability in simulated gastrointestinal fluid, and the average encapsulation efficiency can reach 60%. In-vitro and in-vivo experiments prove that the nano vesicles can efficiently remove senescent cells. The invention has a wide clinical application prospect in the field of anti-aging and inflammation-related disease treatment.

The present invention relates to a drug delivery system platform comprising a transmembrane domain and, more specifically, to extracellular vesicles loaded with a drug delivery system comprising a transmembrane domain and use thereof for treating brain diseases. It was confirmed that the drug delivery system comprising a transmembrane domain, according to the present invention, is maintained in a lipid bilayer when loaded into extracellular vesicles and can bind various active substances to the N-terminus thereof. It was confirmed that the extracellular vesicles loaded with the drug delivery system comprising a transmembrane domain have excellent cellular uptake efficiency, and have excellent effects of cognitive function improvement, neuroprotection, and nerve regeneration when brain disease therapeutic activity-related factors are attached. Therefore, the drug delivery system comprising a transmembrane domain, of the present invention, can have various applications in the drug delivery-related field and the brain disease treatment field.